Antonella d’Arminio Monforte
A5078701955- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- HIV-related health complications and treatments
- Hepatitis C virus research
- Pneumocystis jirovecii pneumonia detection and treatment
- Liver Disease Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
- Hepatitis B Virus Studies
- HIV, Drug Use, Sexual Risk
- COVID-19 Clinical Research Studies
- Viral-associated cancers and disorders
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- HIV/AIDS Impact and Responses
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Polyomavirus and related diseases
- Diabetes and associated disorders
- Tuberculosis Research and Epidemiology
- Bone and Joint Diseases
- Neurological and metabolic disorders
- Syphilis Diagnosis and Treatment
- Pharmacological Effects and Toxicity Studies
Center for Outcomes Research and Clinical Epidemiology
2025
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2025
Ospedale San Paolo
2015-2024
University of Milan
2015-2024
Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo
2016-2024
University of Pavia
2024
Azienda Socio Sanitaria Territoriale Lariana
2020-2023
Association Clinique et Thérapeutique Infantile du Val de Marne
2023
Università Cattolica del Sacro Cuore
2004-2023
Ospedale San Paolo
2008-2022
Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. We provided remdesivir on compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection Patients were those confirmed SARS-CoV-2 who had an oxygen saturation of 94% or less while they breathing ambient air receiving support. received 10-day course remdesivir, consisting 200 mg administered intravenously day 1, followed 100 daily for...
We have previously demonstrated an association between combination antiretroviral therapy and the risk of myocardial infarction. It is not clear whether this differs according to class drugs. conducted a study investigate cumulative exposure protease inhibitors nonnucleoside reverse-transcriptase with
<h3>Background</h3> An increasing proportion of deaths among human immunodeficiency virus (HIV)–infected persons with access to combination antiretroviral therapy (cART) are due complications liver diseases. <h3>Methods</h3> We investigated the frequency and risk factors associated liver-related in Data Collection on Adverse Events Anti-HIV Drugs study, which prospectively evaluated 76 893 person-years follow-up 23 441 HIV-infected persons. Multivariable Poisson regression analyses...
BackgroundHealth care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are utmost importance to patients, clinicians, health-care planners. We examined changes 3 year survival patients starting combination antiretroviral therapy (ART) between 1996 2013.MethodsWe analysed data from 18 European North American HIV-1 cohorts. Patients (aged ≥16 years) were eligible this analysis...
Objective: To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-infected persons, and to investigate any association between such factors, stage HIV disease, use antiretroviral therapies. Design: Baseline data from 17 852 subjects enrolled in DAD, a prospective multinational cohort study initiated 1999. Methods: Cross-sectional analyses CVD at baseline. The collected includes on demographic variables, cigarette smoking, diabetes mellitus, hypertension,...
BACKGROUND. The risk of myocardial infarction (MI) in patients with human immunodeficiency virus (HIV) infection has been assessed 13 anti-HIV drugs the Data Collection on Adverse Events Anti-HIV Drugs (D:A:D) study. METHODS. Poisson regression models were adjusted for cardiovascular factors, cohort, calendar year, and use other antiretroviral association between MI cumulative (per year) or recent (current past 6 months) drugs, >30,000 person-years exposure. RESULTS. Over 178,835...
Objective: To evaluate the frequency of discontinuation first highly active antiretroviral regimen (HAART) and factors predictive discontinuing for toxicity failure in a population-based cohort HIV-positive individuals Italy, naïve from antiretrovirals at enrolment. Methods: The study population consisted who initiated HAART had least one follow-up visit. primary end-points were any component drug failure. Survival analyses performed to identify reaching two end-points. Results: Eight...
The aims of this study were to determine the incidence diabetes among HIV-infected patients in Data Collection on Adverse Events Anti-HIV Drugs (D:A:D) cohort, identify demographic, HIV-related, and combination antiretroviral therapy (cART)-related factors associated with onset diabetes, possible mechanisms for any relationships found.
Across Europe, almost a third of individuals infected with HIV do not enter health care until late in the course their infection. Surveillance to identify extent which presentation occurs remains inadequate across Europe and is further complicated by lack common clinical definition presentation. The objective this article present consensus infection.Over past year, two initiatives have moved towards harmonized definition. In spring 2009, they joined efforts what meant 'late-presenting'...
HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complications, potentially increasing their risk of cardiovascular diseases (CVDs). Furthermore, exposures to some drugs seem be independently associated with increased CVD risk. We aimed develop risk-assessment models tailored patients.Prospective multinational cohort study. The data set included 22,625 from 20 countries in Europe and Australia who were free at entry into the Data collection on...
Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore impact LP on AIDS and mortality. was defined in Collaboration Observational Epidemiological Research Europe (COHERE) as diagnosis with a CD4 count <350/mm(3) or an within 6 months among persons presenting for care between 1 January 2000 30 June 2011. Logistic regression used identify factors associated Poisson AIDS/death. 84,524...
Patients with inefficient CD4+ T-cell recovery on virogically suppressive highly active antiretroviral therapy constitute a major clinical hurdle given the threat of HIV/AIDS disease progression. We show heightened circulating lipopolysaccharide associated plasma enterobacterial DNA and activated Ki67+CD4+CD8+ in 24 immunologic-nonresponders (CD4+ ≤ 200; HIV-RNA 50) compared 11 full responders ≥ 400; 50). These data provide novel insight into INRs pathogenesis, since they correlate augmented...
Several antiretroviral agents (ARVs) are associated with chronic renal impairment, but the extent of such adverse events among human immunodeficiency virus (HIV)-positive persons initially normal function is unknown.D:A:D study participants an estimated glomerular filtration rate (eGFR) ≥ 90 mL/min after 1 January 2004 were followed until they had a confirmed eGFR ≤ 70 (the threshold below which we hypothesized that interventions may begin to occur) or 60 (a value indicative moderately...
Abstract In December 2019, an initial cluster of interstitial bilateral pneumonia emerged in Wuhan, China. A human-to-human transmission was assumed and a previously unrecognized entity, termed coronavirus disease-19 (COVID-19) due to novel (SARS-CoV-2) described. The infection has rapidly spread out all over the world Italy been first European country experiencing endemic wave with unexpected clinical severity comparison Asian countries. It shown that SARS-CoV-2 utilizes angiotensin...